OneSource's Partner Dr. Reddy's Laboratories receives Health Canada Approval For Generic Semaglutide Injection

OneSource serves as the manufacturing partner and provides scale-up and commercial manufacturing of the formulation

OneSource Specialty Pharma Limited today announced that its partner Dr. Reddy’s Laboratories Ltd., has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.

The partnership is designed to ensure reliable and scalable commercial supply from OneSource’s US-FDA approved flagship manufacturing facility in Bengaluru.

Mr. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”

About OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, visit www.onesourcecdmo.com.